AstraZeneca ROA 2006-2018 | AZN

Current and historical return on assets (ROA) values for AstraZeneca (AZN) over the last 10 years. Return on assets can be defined as an indicator of how profitable a company is relative to its total assets. Calculated by dividing a company's operating earnings by its total assets. AstraZeneca ROA for the three months ending September 30, 2018 was 6.46%.
AstraZeneca ROA - Return on Assets Historical Data
Date TTM Net Income Total Assets Return on Assets
2018-09-30 $2.42B $61.44B 3.88%
2018-06-30 $2.68B $61.34B 4.24%
2018-03-31 $2.80B $63.28B 4.38%
2017-12-31 $3.00B $63.35B 4.73%
2017-09-30 $3.54B $64.59B 5.60%
2017-06-30 $3.87B $65.12B 6.15%
2017-03-31 $3.39B $60.96B 5.40%
2016-12-31 $3.50B $62.53B 5.50%
2016-09-30 $2.47B $63.22B 3.91%
2016-06-30 $2.22B $64.42B 3.66%
2016-03-31 $2.92B $64.32B 5.00%
2015-12-31 $2.83B $60.06B 5.07%
2015-09-30 $1.70B $54.12B 3.06%
2015-06-30 $1.18B $55.17B 2.11%
2015-03-31 $1.28B $53.70B 2.25%
2014-12-31 $1.23B $58.60B 2.12%
2014-09-30 $1.03B $56.16B 1.79%
2014-06-30 $2.02B $58.54B 3.55%
2014-03-31 $2.05B $59.39B 3.67%
2013-12-31 $2.56B $55.90B 4.73%
2013-09-30 $4.59B $54.12B 8.57%
2013-06-30 $4.85B $53.99B 9.14%
2013-03-31 $5.63B $52.33B 10.73%
2012-12-31 $6.24B $53.53B 11.99%
2012-09-30 $6.23B $52.45B 12.01%
2012-06-30 $8.19B $51.39B 15.79%
2012-03-31 $8.71B $50.76B 16.62%
2011-12-31 $9.99B $52.83B 18.73%
2011-09-30 $10.13B $52.58B 18.70%
2011-06-30 $8.21B $53.41B 14.89%
2011-03-31 $8.21B $54.53B 14.81%
2010-12-31 $8.08B $56.13B 14.61%
2010-09-30 $8.01B $56.39B 14.56%
2010-06-30 $8.57B $54.65B 15.90%
2010-03-31 $8.16B $54.08B 15.46%
2009-12-31 $7.53B $54.92B 14.79%
2009-09-30 $7.22B $51.90B 14.77%
2009-06-30 $6.84B $50.20B 14.28%
2009-03-31 $6.75B $46.52B 14.10%
2008-12-31 $6.11B $46.78B 12.64%
2008-09-30 $6.14B $48.07B 12.62%
2008-06-30 $5.75B $50.20B 15.67%
2008-03-31 $5.53B $48.46B 15.35%
2007-12-31 $5.58B $47.96B 17.85%
2007-09-30 $5.75B $0.00B 21.47%
2007-06-30 $6.00B $47.60B 17.75%
2007-03-31 $6.20B $29.57B 21.38%
2006-12-31 $6.06B $29.93B 21.72%
2006-09-30 $5.85B $28.12B 21.94%
2006-06-30 $5.48B $28.46B 21.30%
2006-03-31 $5.10B $25.15B 20.53%
2005-12-31 $4.72B $24.84B 19.05%
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $97.289B $22.465B
AstraZeneca PLC is one of the top five pharmaceutical companies in the world based on sales and is a therapeutic leader in cardiovascular, gastrointestinal, oncology, anesthesia including pain management, central nervous system (CNS) and respiratory products. They are engaged in the research, development, manufacture and marketing of ethical (prescription) pharmaceuticals and agricultural products, and the supply of healthcare services.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $389.718B 18.27
Pfizer (PFE) United States $264.307B 14.90
Merck (MRK) United States $208.739B 18.09
Novartis AG (NVS) Switzerland $200.739B 17.21
AbbVie (ABBV) United States $131.784B 11.70
Eli Lilly (LLY) United States $120.858B 21.25
Novo Nordisk (NVO) Denmark $112.280B 18.23
Sanofi (SNY) France $110.782B 13.72
GlaxoSmithKline (GSK) United Kingdom $93.444B 12.56
Bristol-Myers Squibb (BMY) United States $85.821B 14.13